Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
NW Clarke;
A Ali;
FC Ingleby ;
A Hoyle;
CL Amos;
G Attard;
CD Brawley;
J Calvert;
S Chowdhury;
A Cook;
+41 more...
W Cross;
DP Dearnaley;
H Douis;
D Gilbert;
S Gillessen;
RJ Jones;
RE Langley;
A MacNair;
Z Malik;
MD Mason;
D Matheson;
R Millman;
CC Parker;
AWS Ritchie;
H Rush;
JM Russell;
J Brown;
S Beesley;
A Birtle;
L Capaldi;
J Gale;
S Gibbs;
A Lydon;
A Nikapota;
A Omlin;
JM O'Sullivan;
O Parikh;
A Protheroe;
S Rudman;
NN Srihari;
M Simms;
JS Tanguay;
S Tolan;
J Wagstaff;
J Wallace;
J Wylie;
A Zarkar;
MR Sydes;
MKB Parmar;
ND James;
STAMPEDE investigators;
(2020)
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
ANNALS OF ONCOLOGY, 31 (3).
442-.
ISSN 0923-7534
DOI: 10.1016/j.annonc.2020.01.002
The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.
Item Type | Article |
---|---|
Elements ID | 144961 |
ORCID: https://orcid.org/0000-0003-1800-2015